Replies to post #3509 on Rexahn Pharmaceuticals, Inc. (REXN)

[Valensio]

It was a voluntary r/s, I don't think a lot of retail investors know that. I think a lot of people think it was the usual reason most bio's are forced to do it, to get compliance with a $1 share price requirement, which rnn isn't required to do. This was solely by choice only to get the pps higher to a level where bigger institutions can invest in rnn now since many are forbidden to invest in a stocks below $5/share & some $1/share. It wouldn't surprise me if they had a partnership in works or a bigger pharma waiting to buy in once this new higher post r/s share price takes effect.

[pearsby09]

First of all I think there will be a cash raise with a premium at 4.25, raising the OS to 45 million. To answer your question whether this is a good move or not depends on the strength of the 4 2017 catalysts. I am hoping we do not drift back into the 2's and 3's post R/S prior to results.

[BLUEVOODU]

For the time being... expect rough seas.

Psychologically... this will weigh heavy on most minds. Even for the seasoned... it can be a bit tough.

If they don't have good news after the R/S... or if major value is lost... we will probably see the stock hit lower than last year.

Not sure this is a good time to hold.